This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Well, I'm making the effort to understand, but I can't cross relate at all.

That's it, I have had enough.

BB ramper methinks.

220p bid per share rejected by DB as too low.

Nice to be back in old blitey and a reliable PC to use again albeit 2,000 plus e-mails queing up aghhhhhh............... The spanish are great improvisers but I didnt fancy a water tap being attached to my lap top so Ive been rather quiet whilst on my crusades abroad in the last 8 weeks.

Anyway this is the first post from old faithfull and I can tell you although you may already know Evil K as now gone long, this taken from another freebie site....

My point is that having made money shorting Medical Marketing (MMG) I am now on the long tack and the shares are heading my way yet again. there was something in the Telegraph today about gene thereapy.

Looks like its had a knock on effect alongside the world wide news from the yanks yesterday.

cheers GF.

PS, hoping to join you full time monday after a weekend of drinking stella (proper beer) instead of the piss poor stuff Ive had of late.

Welcome back to the party gf.

Best won't let it go that low. He knows what he's got and what potential MMG has. The big names were brought on board for a reason. Read below as I think this is an important link in the chain.

MMI announces new Non-Executive Director

20/07/2006

July 20th 2006. Medical Marketing International Group plc ('MMI' or the 'Company'), the UK-listed virtual pharmaceutical development company focused on drugs for the treatment of cancer and infectious diseases, traded on the AIM market of the London Stock Exchange (AIM:MMG), today announces the appointment of Dr. Mike Rance as Non-Executive Director. Dr. Rance will take up his position with MMI at the company's AGM on September 20th 2006.

Dr. Rance, 60, is Vice-President, Corporate Affairs at AstraZeneca where is he responsible for the company's investor relations and public affairs functions. As a trained Chemist, Dr Rance joined ICI Pharmaceuticals in 1983 where he initially managed a group of 50 scientists engaged in pain and CNS research. He subsequently held various product development and marketing posts at ICI and then Zeneca Pharmaceuticals where he was head of business development during the merger between Astra and Zeneca. Dr. Rance was also a member of the corporate integration team managing the merger between the two companies. Dr. Rance will be retiring from his position at AstraZeneca at the end of July 2006.

David Best, Executive Chairman of MMI, said:

'We are delighted that someone of Mike's experience is joining us. His experience gained from working in investor relations for Astra Zeneca will be invaluable to MMI, as will his time spent working in drug development. We believe that Mike will be a huge asset to us as we transition into a pharmaceutical development company'

Mike Rance said:

'I have been very impressed at the depth of MMI's product pipeline and at the high quality of the work being conducted by the team there. The company is clearly operating to the highest standards and I look forward to working with them as they progress their compounds through the clinic'.

Dr. Rance is currently a Non-Executive director of MNL Pharmaceuticals Limited and is a Member of the Board of Trustees of the AstraZeneca Science Teaching Trust.

LOL
MS

Yes welcome back GF. Hope you had a good time and have several stellas on me over the week end. Do get pissed as I no doubt will be. Lets hope England get a decent result to make up for a crap world cup.

LOL
MS

Hi lads caught me just before I set off on my over indulgence fest.

Nice to be back with you guys.

Will see you monday.

cheers GF.

I'm still puzzled about ERX.

From what I see there is a 50/50 chance it is them who have had the two cures for cancer using gene splitting.

Ther are apparently only two companies who deal with this technology as they have patents for it.

MMG deal in dna unravelling as I understand it, am I right in respect of MMG?

Surely one of you inestors knopws the answer to the above, do mmg deal with dna technology?

From the other side. SW I don't think they are into dna technology. Try their web site it's been updated. A lot of speculation going on and someone is buying big time.

bolador - 2 Sep'06 - 12:19 - 7576 of 7643


kenmill,

Yes more likely but bitterly disappointing from a shareholders point of view
since an initial jump in the sp would be followed by a drift down as it was realised that "thats that for a while" and no bonanza either.
However at a recent presentation DB told those present that MMI had commissioned a valuation of the business by a senior city institution and that
they had come up with a figure well in excess of the current sp. In conversation after the meeting this was confirmed by DB. I therefore believe the possibilty of MMI accepting a bid, full or partial, at around 230p to be
an absolute non starter. Moreover I do not believe that DB and his team will ever place themselves in a position where they have to operate within the
red tape atmosphere of a mega corp without having secured their fortune first.
I have had two conversations with DB at presentations and am convinced that he
believes that the value of the MMI portfolio is way in excess of the current
mkt cap and that he intends tp prove it. For what its worth that's my view.

Hi SeaWW, mitzy is the medical expert re to the question you put.

Have to say Im a number cruncher and look at an investment on a risk reward basis. MMG is the highest risk stock in my portfolio on that basis, but as a tranche investor it as served me well so far although I hold some tranches at a loss. Sorry I couldnt be of more help.

Nice to see it on the up anyway and I dont really go in much for bid speculation etc, until I see the finished article.

Cheers GF.

Might be Evil K who is buying big time Mickey, he left me a message sunday saying fill yer boots here, dont think he knows Im in.

I'm happy to hear that Glaxo is interested in buying 9% of the company and not contemplating a full bid so glad they are onboard as the next few years could be very exciting indeed.

Hi Mitzy, been away for a while so not up to date, whats the source for the Glaxo news?. Nice to see you back here by the way.

cheers Gf.

Hi gf read in the news last week that Glaxo wish to acquire 9% of MMI and are not making a full bid for them which is a relief..I'm happy to hold mine for 1500p plus in the next 2 years.

A good post from the other side.

el magnifico - 5 Sep'06 - 22:15 - 7651 of 7655


dadob1

I suppose it depends on your timeframe. I'm packing away the summer hammock and waiting for the 20th September AGM at NCL, 25 Moorgate for a gentle update.

Looking across at OXB, which had languished to a low of 19.5p until late August and is 31.25p today, following its AGM and update, MMG could appreciate to 210p, from the 140-ish lows seen recently.

IMHO OXB is a similar, though inferior, proposition to MMG, valued at 160 million pounds pre-deal for Trovax, or further Prosavin outcomes. MMG's (a) GenVax and (b) Oncosense platforms are more exciting as (a) cancer vaccine breakthrough and (b) replacement for platinum cancer therapies, and both address huge potential markets. I'm sure that this proposition is debatable, but I hold it to be correct after several years of owning both.

As to the recent MMG bid speculation, I can only agree that DB is developing a bidding environment for specific rights to the GenVax and Oncosense properties. I envisage a bid for the whole of MMG to be a pipedream, although a share subscription for a minority stake and a royalty payment structure for specific GenVax / Oncosense rights (maybe thin-sliced by therapeutic application)would be a runner.

I recall that a previous investment of mine, UK internet provider Unipalm, was bid for by UUNET in the late 1990s, which was in turn quickly bid for by WorldCon (sic). I can only hope that DB stays the course, holds out for rich licensing deals on a drug-by-drug basis, rather than sell out quickly and cheaply, and makes himself and long-term MMG holders Microsoft-rich, rather than WorldCom-rich.

IMHO we're on track for the maximal outcome (9 out of 10 major Pharmas on GenVax can't be wrong!). Oncosense's ruthenium therapies have yet to come under starter's orders for usurping the poisonous 30-year old platinum cancer therapies.

After a somnolent summer, we are in for an enlightening period ahead.

No timeframe, leave that that to the traders. Valuation, 500p minimum . Sounds a lot from here (that's 1/2 billion quid-ish) - but remember we were >1/2 way there at 300p in March 2005, before the last 18 months of succesful GenVax trials and the massive academic flux into the Oncosense platform.

As the appetite for genuine bio-blockbusters gathers momentum, this sober MMG site will become a lightning-conductor.

Good luck to all long-term investors !

el

GF

You have email. Pick up asap.

MS

From the other side.

A0469514 - 6 Sep'06 - 13:30 - 7658 of 7661


I agree with el magnifico that a full bid for MMG is very unlikely given the number of shares controlled by Best and his wife. It is however very plausible that Glaxo would be in the forefront of negotiations for a slice of the action in some of MMG's product pipeline. Genvax, in particular, would seem to fit very well into GSK's vaccines business which they have been expanding aggressively in recent years.

I suppose that Best could agree to sell MMG's stake in the Genvax programme to the highest bidder and distribute the proceeds to shareholders via a special dividend. However Best would pay an awfull lot of tax doing it that way so it is unlikely.

By far the most likely imo is a deal where someone like Glaxo takes on the further development and future marketing of Genvax and pays an upfront fee, milestone payments as development progresses and then royalties on product sales. In that way MMG's shareprice would receive a massive boost and, if Best's confidence in his product is justified, it would carry on improving in the years ahead when it becomes clear that the products will hit the market and likely be blockbusters.

The problem is that when you are negotiating with 9 of the top ten pharma companies it is certainly not going to be a quick process and it is very difficult to predict when a deal may be clinched. My guess though is that both the Genvax and ruthenium programmes are close to a stage where some big money and a heavyweight partner could be very useful to Best's ambitions for the company. For this reason, I believe that the announcement of a huge deal could be close.

Xylos

Cheers for the info on Glaxo Mitzey.

Mickey, PM gone through to you.